Insider Selling: Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock

Xencor, Inc. (NASDAQ:XNCR) VP John Desjarlais sold 2,663 shares of Xencor stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $11.90, for a total transaction of $31,689.70. Following the completion of the transaction, the vice president owned 270,451 shares in the company, valued at approximately $3,218,366.90. This trade represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Xencor Trading Up 1.4%

XNCR stock opened at $11.32 on Friday. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12. The company has a market cap of $830.21 million, a price-to-earnings ratio of -9.13 and a beta of 0.95. The business has a fifty day simple moving average of $12.79 and a 200-day simple moving average of $12.93. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $18.69.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million for the quarter, compared to analysts’ expectations of $29.97 million. During the same quarter last year, the firm earned ($0.62) earnings per share. The firm’s revenue for the quarter was down 46.6% compared to the same quarter last year. On average, equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on XNCR. Truist Financial began coverage on Xencor in a report on Monday, November 24th. They set a “buy” rating and a $29.00 target price for the company. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Barclays lifted their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Xencor currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Institutional Investors Weigh In On Xencor

Several institutional investors and hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new stake in shares of Xencor during the 4th quarter valued at about $1,677,000. Invesco Ltd. lifted its position in Xencor by 5.7% during the 4th quarter. Invesco Ltd. now owns 265,820 shares of the biopharmaceutical company’s stock worth $4,070,000 after acquiring an additional 14,216 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in Xencor in the 4th quarter worth approximately $202,000. XTX Topco Ltd acquired a new stake in Xencor in the fourth quarter valued at approximately $490,000. Finally, Voloridge Investment Management LLC acquired a new stake in Xencor in the fourth quarter valued at approximately $1,343,000.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.